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Abstract
Importance—Autologous hematopoietic stem cell transplantation may be effective in aggressive
forms of multiple sclerosis that failed to respond to standard therapies.
Objective—To evaluate long-term outcomes after autologous hematopoietic stem cell
transplantation for treatment of multiple sclerosis.

Author Manuscript

Design, Setting and Participants—Data was collected in a multicenter observational
retrospective cohort study. Eligibility criteria were having received autologous hematopoietic stem
cell transplantation for the treatment of multiple sclerosis during 1995–2006 and availability of a
pre-specified minimum dataset, comprising the disease subtype at baseline; the expanded
disability status scale (EDSS) score at baseline; information on the administered conditioning
regimen and graft manipulation; and availability of at least one follow-up visit/report after
transplantation. Last patient last visit was on July 1, 2012. To avoid biases, all eligible patients
were included in the analysis regardless the duration of follow-up.
Exposures—Demographic, disease- and treatment-related exposures were considered as
variables of interest. These included age, disease subtype, baseline EDSS score, number of
previous disease modifying treatments, and intensity of transplantation conditioning regimen.
Main Outcomes and Measures—The primary outcomes were multiple sclerosis progressionfree survival and overall survival. The probabilities of progression-free and overall survival were
calculated using Kaplan-Meier survival curves and Cox regression multivariate analysis models.

Author Manuscript

Results—Valid data was collected from 25 centers in 13 countries for 281 evaluable patients
with median follow up of 6.6 years (range 0.2–16 y). The majority of patients had progressive
forms of multiple sclerosis (78%). The median EDSS score prior to mobilization was 6.5 (range
1.5–9.0). The five-year probability of EDSS progression free survival was 46% (95% confidence
interval [CI], 42–54 %) and overall survival was 93% (95% CI, 89–96 %). Factors associated with
neurological progression post-transplantation were age (HR=1.03, 95% CI, 1.00–1.05),
progressive vs. relapsing forms of multiple sclerosis (HR=2.33, 95%CI, 1.27–4.28) and >2
previous disease-modifying therapy (HR=1.65, 95%CI, 1.10–2.47). EDSS score was associated
with worse overall survival (HR 2.03, 95%CI=1.40–2.95).
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Conclusions and Relevance—In this observational study of MS patients treated with
autologous hematopoietic stem cell transplantation, nearly half survived free from neurological
progression for 5 years after transplantation. Younger age, relapsing multiple sclerosis, less prior
immunotherapies and lower disability score were factors associated with better outcomes. The
results support the rationale for further, randomized controlled studies of AHSCT for treatment of
MS.

INTRODUCTION
Approximately 3 million people in the world have multiple sclerosis (MS). 1 MS typically
presents in young adulthood and can cause severe neurological disability, a major socioeconomic burden 2. Patients with an aggressive course of MS often fail to respond to several
lines of disease-modifying treatment and deteriorate within a few years.

Author Manuscript
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Autologous hematopoietic stem cell transplantation (AHSCT) is being investigated as
treatment for aggressive MS3. The rationale of this approach is to allow the use of high dose
immunosuppressive therapy to abrogate the autoimmune inflammatory process. Infusion of
autologous hematopoietic cells boosts bone marrow recovery and promotes immune
reconstitution. The procedure has been shown to induce a degree of immune ‘resetting’ 4,5.
The treatment goals are to arrest worsening of neurologic disability, induce a prolonged
medication-free interval and potentially an improvement in neurological function. Early
clinical trials established the proof of principle that AHSCT could induce disease remissions
in patients with severe MS 6. More recent studies have shown that autologous AHSCT is
effective at suppressing clinical and magnetic resonance imaging (MRI) disease
reactivations 7–9, can result in neurological improvement in patients with relapsing-remitting
MS 7,8,10–12 and can halt all detectable CNS inflammatory activity for a prolonged period of
time 13. However, outcome assessments in the majority of studies were limited to a relatively
short follow-up, and longer-term outcomes have been reported only from small case
series 14–16. It would therefore be important to examine in a large patient population the
course of MS after AHSCT and the rates of risks and complications over longer term.
The objective of this study was to evaluate long-term outcomes in patients who underwent
AHSCT for treatment of MS in a large multi-center cohort by analyzing progression-free
survival, evolution of neurological disability, overall survival, transplant related mortality
and late effects, including new autoimmune and malignant disorders; and to examine the
association of demographic, MS disease- and treatment-related variables with the long-term
outcomes.

Author Manuscript

METHODS
Study Design, Setting and Data Sources
This study was an observational retrospective cohort study on autologous AHSCT for
treatment of MS and was performed through collaboration between the Center for
International Blood and Marrow Transplant Research (CIBMTR) Autoimmune Disease
Working Committee and the European Blood and Marrow Transplant Group (EBMT)
Autoimmune Disease Working Party. The CIBMTR is a voluntary working group of more
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than 450 transplant centers worldwide that contribute detailed data on consecutive marrow
transplants to a Statistical Center located at the Medical College of Wisconsin in Milwaukee
and at the National Marrow Donor Program Coordinating Center in Minneapolis.17 The
EBMT is a non-profit organization comprising 640 transplant centers mainly from Europe.
All transplant centers have been required to obtain written informed consent to report data to
the CIBMTR and to the EBMT database in accordance with the Helsinki Declaration 1975.
Institutional Review Board approval for data collection and use of data for research purposes
was obtained locally by each center. Only fully anonymised data were transferred to the
study database. Following review by the study Steering Committee, the study protocol
(Supplementary Appendix 1) was approved by the CIBMTR and the EBMT Board in
agreement with the rules for retrospective studies of both organisations. MS pre-transplant
and follow-up data had been prospectively collected from participating transplant centers on
disease specific forms, which were harmonized between the two registries.18 For the
purposes of this study, all bone marrow transplantation centers that had reported at least one
autologous AHSCT for MS to CIBMTR or EBMT between 1995 and 2006 were sent an
invitation to participate in the study together with a protocol summary. The centers that
agreed to participate were asked to identify a transplant physician and a neurologist to
oversee all patient data for accuracy and completeness at each site. To better describe disease
activity before and after transplant and extend the follow up for our study, additional data
collection was undertaken retrospectively. To this end, the Study team developed a
supplemental data collection form that was pre-populated with the previously reported data
in order to facilitate additional data collection and concurrently verify the accuracy of
existing information. The overall completeness of enrollment in our study, calculated as
percentage of all the procedures reported to the two registries during the time period, was
281/493 (57%). A CONSORT diagram of enrollment and screening of the potentially
eligible cases in provided in eFigure 1). Our study is reported according to the STROBE
guidelines (checklist in supplementary Appendix).
Patients and Treatments

Author Manuscript

For each case to be included in the study a minimum dataset was required, which comprised:
the MS course classification at baseline (relapsing remitting, RR; primary- PP or secondary
progressive, SP; progressive relapsing, PR); the expanded disability status scale (EDSS;
ranging from 0 signifying no disability through 7 for wheelchair bound to 10 for death due
to MS; see eTable 1 for a detailed description) score at baseline; information on the
administered conditioning regimen and graft manipulation; and availability of at least one
follow-up visit/report after transplantation. Mobilization of Peripheral Blood Stem Cells
(PBSC) was carried out by the administration of a hematopoietic Growth Factor (GF), with
or without chemotherapy; type of both GF and chemotherapy were sought. Manipulation of
the graft aimed to reduce the content of immune cells was also requested. Conditioning
regimens including either Busulphan or Total Body Irradiation (TBI) were classified as high
intensity; regimens including Cyclophosphamide alone or associated to Anti-Thymocyte
Globulin (ATG) or Fludarabine were classified as reduced intensity; all the others were
considered as intermediate intensity.
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Progression-free survival was defined as survival in the absence of progression of MS.
Progression of MS was defined clinically as an increase of 1 point in the Expanded
Disability Status Scale (EDSS) confirmed at 12 months (0.5 points if baseline EDSS score
was >=5.5) compared to the pre-treatment baseline. The pre-treatment baseline was defined
as the last assessment before mobilization (for peripherally mobilized autologous grafts) or
before immunosuppressive conditioning (for bone marrow autologous grafts). EDSS
increases that were detected on the last visit and therefore cannot be confirmed were
considered as events, according to a more conservative approach. A sensitivity analysis was
run censoring these last visits events. Death by any cause was considered MS progression in
this analysis. Overall survival was time to death by any cause. For all the patients who died
after the AHSCT the cause of death was examined. Early deaths that occurred within 100
days from transplant, which are considered treatment-related, were described separately.
Surviving patients were censored at time of last follow-up. Information regarding the
incidence of late effects was collected, including malignancies and secondary autoimmune
diseases.
Statistical Analysis

Author Manuscript

Data collected from both the CIBMTR and EBMT were summarized in descriptive tables of
demographic information of all the population. Continuous variables were reported as
medians and ranges or means and standard deviations, while categorical variables were
reported as absolute numbers and percent of total patients. The probability of progressionfree survival was calculated using the Life Table estimator and the overall survival was
calculated using the Kaplan-Meier Estimator. A multivariate analysis assessing the
association of baseline characteristics and transplant methodology on progression free and
overall survival was run using Cox proportional hazards regression models, adjusted for
center. Proportionality of hazard was checked by plotting log-log transformation of the KM
survival curve, namely, log-log(S(t)), versus time t for each level of covariates; the
assumption of proportional hazard is tenable if the difference between the two log-log KM
curves is constant over time.

Author Manuscript

Variables significantly associated with each outcome event at univariate analysis were
included as covariate in the multivariate model, which selected the independent set of
variables using a stepwise approach. For each patient having an EDSS assessment 1 year
before and 1 year after transplant, the yearly EDSS changes pre and post-transplant were
calculated. These changes were compared by a repeated measures analysis of variance with
2 time points (change pre vs change post-transplant), including also disease type (relapsing
vs progressive forms) and an interaction term (period by disease type) to evaluate whether
the EDSS change pre and post-transplant was different between relapsing and progressive
patients.
A Loess smoothing technique 19 was applied to describe the EDSS trend over time in
relapsing and in progressive patients, for those subjects having EDSS date of assessment
reported. The Loess technique is a non-parametric, graphical tool to fit a smooth curve to the
points in a scatterplot, based on local weighted regression analyses 19.
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A two-sided significance level of 5% was used. We used R version 3.2 and SPSS version 19
software for the analysis.

RESULTS
Patients Demographics and Procedures

Author Manuscript
Author Manuscript

Valid data was obtained for 281 patients. Demographic and clinical data at the time of
AHSCT are summarized in Table 1. The median disease duration calculated from diagnosis
of MS to AHSCT was 81 months (range 1–413). At the time of AHSCT, 171 patients (61%)
had received 2 or more prior lines of disease-modifying treatment for MS. At the assessment
preceding mobilization the most represented disease subtype was SPMS, contributing 186 of
the 281 patients (66%), and the median EDSS score was 6.5 (range 1.5–9) indicating
moderately advanced disability on average. A few differences existed in the subsets of
patients reported to CIBMTR and EBMT reflecting different patient selection practices in
the two groups of countries. Compared to the CIBMTR cohort, patients from the EBMT
cohort were younger (median age 35 years vs. 40 years, p<0.001), had more often >2 lines
of therapy prior to transplant (52% vs. 32%, p=0.002), had less patients in SP (61% vs.
75 %, p=0.001), shorter time from diagnosis to transplant (median time of 77 months vs. 91
months, p=0.04) and had a greater proportion of patients transplanted during the first half
(1995–2000) of the 12-year period qualifying for inclusion in our study (42% vs. 22%,
p<0.01). In total, however, two thirds of the patients underwent AHSCT during the second
half (2001–06). Mobilisation, graft manipulation and conditioning regimens details are also
summarized in Table 1. The proportions of patients who received high-, intermediate- and
low-intensity conditioning regimens were evenly split (approximately one third each) in
CIBMTR, whereas 89% of patients reported to EBMT received an intermediate intensity
regimen (most commonly BEAM+ATG). The percentage of patients treated with highintensity regimens was higher in progressive (20%) than in relapsing (10%) patients
(p=0.05). The median duration of follow-up post-AHSCT was 6.6 years (range 0.2–16).
Progression-free survival

Author Manuscript

Progression-free survival as assessed by EDSS was considered the primary neurological
endpoint. Patients with yearly EDSS assessments post transplant enabling this analysis were
239 (85%). MS progression-free survival in all evaluable patients was 46% at 5 years postAHSCT (CI 42–54%; Fig. 1A). Progression-free survival in the subgroup with relapsing MS
was 82% at 3 years (95% CI 71–93%), 78% at 4 years (95% CI 66–91%) and 73% at 5 years
post-AHSCT (95% CI 57–88%). Amongst patients with SPMS, the largest subgroup in our
study (n=162), 33% (95% CI 24–42%) remained free from EDSS deterioration at 5 years
post-AHSCT. When applying a Cox regression analysis, the assumption of proportional
hazard was tenable. Factors associated with the risk of EDSS progression as identified by
univariate Cox analysis were: age; progressive vs. relapsing phase/subtype of MS; and
number of prior treatments (Table 2). The significance of these factors was confirmed at
multivariate analysis (Table 2; Fig. 1B, C, D). Younger age and relapsing forms of MS were
independently associated with better progression-free survival (Fig. 1B, C). There was no
statistical difference in the risk of progression between PPMS patients and SPMS (HR=1.09,
p=0.63)(Fig. 1C). Patients who had received 3 or more immune-suppressive/modulatory
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treatments had a higher probability of progression than those who received 1–2 treatments
before AHSCT (Fig. 1D). The results did not change when the unconfirmed progressions on
the last visits were considered censored observations.
EDSS change in the period preceding and after AHSCT

Author Manuscript

It was important to also consider the evolution of neurological disability in the patients
before they underwent AHSCT and the information was available in a subset of patients in
the cohort. There were 111 patients who met the minimum requirement for this evaluation
consisting of availability of at least one EDSS score during the three years prior to as well as
after AHSCT with the respective dates of assessment. In the evaluable subgroup, the mean
EDSS increased by 0.94 points (95%CI= 0.77–1.11) during the 12 months preceding
transplant, as compared to a mean decrease of −0.32 EDSS points (95%CI= −0.15, −0.49) in
the 12 months following transplant (p<0.001). A test for interaction demonstrated that the
evolution of EDSS change pre and post-transplant was significantly different between
patients with relapsing MS [EDSS change 1 year pre-transplant = +1.42 (95%CI= 0.98–
1.86), EDSS change 1 year post-transplant = −0.76 (95%CI=−1. 08-0.34)] and progressive
MS forms [EDSS change 1 year pre-transplant= +0.73 (95%CI= 0.59–0.87), EDSS change 1
year post-transplant = −0.14 (95%CI=−0.28 - 0.01)] patients (p<0.001). Figure 2 shows the
evolution of EDSS score recorded before and after AHSCT in the 111 patients, divided by
disease course in relapsing (A) and progressive (B) MS types. This representation allows
visualizing the rapid neurological deterioration occurring in both patient subgroups before
AHSCT. Post-transplantation, the integrated line suggests a reduction of the rate of accrual
of disability in the subgroup with relapsing MS (Figure 2A).
Overall survival

Author Manuscript

Overall survival was 93% (95% CI,=89–96%) at 5 years and 84% (95% CI= 78–89%) at 10
years from transplant (Figure 3A). When applying a Cox regression analysis, the assumption
of proportional hazard was tenable. Factors associated with worse overall survival at
univariate Cox analysis were: age; baseline EDSS score; high vs. low intensity of the
conditioning regimen; progressive vs. relapsing form of MS (Table 2). At multivariate
analysis only a higher baseline EDSS score remained significantly associated with a higher
risk of death over time with HR 2.03 per EDSS point (95%CI=1.40–2.95; Table 2). When
stratifying by disability levels, Kaplan-Meier analysis revealed worse survival in patients
with baseline EDSS ≥ 7 (p = 0.004, Fig. 3B).
Mortality and late adverse events

Author Manuscript

Overall, 37 deaths from any cause (treatment related or not) out of 281 patients were
reported during the entire follow-up. Eight deaths (2.8%, CI=1.0–4.9%) were reported
within 100 days from transplant and were considered transplant related mortality. Data on
factors associated with lower overall survival at univariate analysis are presented for the
patients who died within and after day 100 post-transplant against the whole cohort in
eTable 2. Among the patients who died during follow-up, progressive MS type and high
intensity conditioning regimens were overrepresented compared to the frequency of these
factors in the whole cohort. However, the small number of events precludes a formal
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statistical evaluation. Individual causes of death and details on previous immune
suppressive/modulatory treatments for MS are provided in eTable 3.
Late adverse events including the new onset of malignancies and autoimmune diseases are
reported in eTable 4. Additionally, one case of Monoclonal Gammopathy of Unknown
Significance (MGUS) was reported. Of the 3 cases of myelodysplastic syndrome two
received a total body irradiation-based regimen and the other received cyclophosphamide
+ATG. In the small number of events occurred, there was no clear evidence to suggest
association of any of the late events with specific treatment regimens.

DISCUSSION
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Previous studies of AHSCT for treatment of MS often reported detailed assessments, some
including MRI endpoints, yet most had relatively short duration of follow-up: for example in
the largest published prospective study (n = 145) median follow-up was 2 years11. The few
studies with truly long-term follow-up (i.e. including outcomes at 5 years) included small
numbers of patients, the largest reporting on 35 patients over a median follow-up period of
11 years 15. We analyzed a large cohort of patients undergoing AHSCT for treatment of MS
(n = 281) over long term (median follow up of 6.6 years). Compared to the largest
previously published cohort (Burt et al11) that included 118 RRMS (81.4%) and 27 SPMS
patients (18.6%) our study includes a different proportion of MS types where 63 patients had
relapsing types (RRMS and PRMS totaling 22.4%) and 218 had progressive types (PPMS
and SPMS totaling 77.5%), thus it provides more information on outcomes after AHSCT in
progressive MS, an area of unmet need20. Burt and colleagues noted that their criteria
selecting patients with active inflammation and excluding those with late secondaryprogressive MS may have prevented them from detecting associations that may exist with
baseline EDSS score, older age, or prior number of immune-modulation or suppression
regimens with a worse outcome11. In our study, not imposing any criteria to select a disease
phenotype enabled us to demonstrate significant associations of these factors with worse
outcomes. Lastly, all previous studies focused on specific AHSCT protocols utilized at those
centers whereas in our study, for the first time to our knowledge in a long-term cohort, we
report outcomes after a wide range of regimens, including low- (17%), intermediate- (64%)
and high-intensity regimens (19%) and include conditioning intensity as a variable in the
statistical analyses.
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Our primary neurological outcome was progression-free survival, as assessed by systematic
EDSS neurological disability scoring. In our cohort 78% of patients had PP- or SPMS and
the observed progression-free survival in the evaluable patients (239/281, 85%) was 46% at
5-year follow-up. Because long-term stability of neurological disability is not an expected
feature of the natural course of aggressive forms of relapsing or progressive MS21 these data
raise the possibility that AHSCT may have reduced the risk of progression in the treated
patients, yet in the absence of a control group demonstration is lacking. Neurological
outcomes in our study, however were considerably better in patients with relapsing- than in
those with progressive MS, consistent with recent evidence of good efficacy in RRMS7,11.
By using multivariate analysis we identified relapsing MS as a factor robustly associated
with progression-free survival (HR=2.33), which remained >70% at 5 years post-AHSCT in
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this patient subgroup. In the report by Burt et al, 81.4% of the patients had RRMS and
progression-free survival was 87% at 4 years 11. In the HALT-MS trial patients were all
RRMS by inclusion criteria and progression-free survival was 90.9% at 3 years 7. Inclusion
criteria selecting patients with early RRMS may explain the higher progression-free rates
observed in those studies. Additional factors that were significantly associated with better
progression-free survival in our study were younger age and less than 3 prior MS diseasemodifying treatments. Some of the previous studies considered age in subgroup analyses22
but none to our knowledge demonstrated their significance through formal statistical
evaluation. Furthermore, we analyzed in a subset of evaluable patients the trajectory of
neurological disability as measured by EDSS during the periods preceding and following
AHSCT. The mean accumulation of disability during the 12 months pre-transplant (+0.94
EDSS points) was partially reversed post-transplant (−0.32 EDSS points) and the reversal
was significantly greater in the patients with the relapsing compared to the progressive MS
forms. This comparison extends previous observations of improvements in EDSS scores
after AHSCT in studies including predominantly or exclusively RRMS patients 7,8,10,11 and
in the subgroup of patients with RRMS of the Italian AHSCT database 12.
We also examined the association of variables with overall survival. Univariate analysis
identified age, baseline EDSS score, intensity of the conditioning regimen and progressive
vs. relapsing form of MS as factors significantly associated with lower overall survival rate.
Of these, only baseline EDSS score was confirmed as significant in multivariate analysis,
with a HR=2 per EDSS point. However, the low rate of events limits the power to detect at
multivariate analysis all the variables underlying mortality and we cannot conclude that
factors like conditioning intensity or disease stage do not affect survival.
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Transplant-related death is a major concern in a non-immediately life-threatening disease
such as MS. In the present study the 100-day mortality, which in hematological practice is
considered a surrogate of transplant related mortality, was 2.8%, a high rate that likely
reflects the early AHSCT experience captured in our study that only included transplants
performed until 31/12/2006. Indeed, a retrospective analysis of the EBMT Registry
performed in 2007 reported a decrease of treatment-related mortality from 7.3% to 1.3% in
transplants for MS carried out before and after the year 2000, respectively3. In a 2010
update23, the 100-day mortality in the whole Registry was 2%, half of that in the 2005 report
(4%)24. The reduction over the years is likely related to improved selection of patients with
the exclusion of patients with advanced disability who are at higher risk of complications,
and to the less frequent use of intensive conditioning regimens 22. In our study the causes of
deaths within day 100 were partly related to the immunosuppression, as expected 22
although the small number of events prevents a reliable analysis. Beyond day 100, the
incidence of death is scattered throughout the follow-up (Fig. 3 and data not shown) and the
causes can be attributed in large part to progression of MS disability and its attendant
complications, which often include infection even in patients who have not been treated with
immunosuppressant therapies. The conditioning regimen was more frequently a highintensity one in the patients who died during follow-up than in the whole cohort, yet nonrandom allocation of treatment and small numbers prevent us from making definitive
conclusions about this association.
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The analysis of late events included malignancies and new onset of autoimmune disease.
With regard to malignancies, 3 patients (1%) were reported with a myelodysplastic
syndrome, a disorder associated with prior treatment with cytotoxic drugs; the other
neoplasms reported in this cohort are usually not associated to previous chemotherapy. The
incidence of new autoimmune disease was not negligible (5%), in line with a survey recently
carried out by EBMT 25, yet considerably lower than after lymphocyte-depleting treatment
with alemtuzumab that approaches a risk of 50%26.
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The main limitation of our study is its partially retrospective nature. Although some of the
data was collected retrospectively from clinical records, we took many steps to optimize the
analysis. As most database studies, the reported outcomes mirror the practice for MS
treatment in many countries. EDSS assessments were not rater-blinded and not
systematically performed for the duration of follow-up in every patient, thus we limited the
analysis of progression-free survival to the large subset of patients (85%) who had yearly
EDSS rating. The number of patients with enough data points for the different analyses was
variable and sometimes low, which reduced statistical power. In a retrospective study
incomplete reporting and loss to follow-up may result in underestimating the frequency of
late adverse events. We also acknowledge the limitation that although our analysis includes
the majority (57%) of the transplants registered with CIBMTR and EBMT during the time
period, more than one third of the activity was not captured by our study. However, the
reason for 166/212 (78%) of the unavailable cases was that the centers where the patients
were treated declined to participate in the study; 43 (74%) out of 58 centers which did not
join the study had performed less than 3 transplants and lack of incentive for the clinicians to
contributing few cases to a large study was stated in many centers’ responses. Based on this
information we do not expect that the unavailability of those cases could represent a
significant source of bias.
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In summary, in this large observational cohort of MS patients with predominantly
progressive forms of MS treated with AHSCT and followed long-term, almost half survived
free from neurological progression for 5 years after transplantation. Taken together, the
multivariate statistics indicate that the profile of a patient who is more likely to survive free
from neurological progression is that of a younger subject with relapsing MS who has failed
no more than two disease-modifying treatments and has not reached high levels of disability.
These associations strengthen the case for an evaluation of safety and efficacy of AHSCT in
a randomized controlled trial against approved therapies of high efficacy as first- or second
line of treatment in patients with highly active relapsing MS, as suggested by experts’
consensus 27. Furthermore, our results raise the question whether AHSCT may attenuate the
progression of disability in patients with progressive forms of MS, a possibility that is more
plausible in patients with MRI evidence of CNS inflammatory activity pre-transplant 8,12,15
and that could be addressed in a randomized trial of AHSCT controlled against standard
care.
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Key Points
Question
What are the long-term outcomes following autologous hematopoietic stem cell
transplantation for treatment of multiple sclerosis?
Findings
In this multicenter observational retrospective cohort study of 281 patients with
predominantly (78%) progressive forms of multiple sclerosis who underwent autologous
hematopoietic stem cell transplantation during 1995–2006, transplant-related mortality
was 2.8% and neurological progression-free survival was 46% at 5 years. Relapsing
multiple sclerosis, younger age, less prior immunotherapies and lower neurological
disability score were significantly associated with better outcomes.
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Meaning
The results support the rationale for further, randomized controlled studies of autologous
hematopoietic stem cell transplantation for treatment of multiple sclerosis.
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Figure 1. MS progression-free survival
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Probabilities of EDSS progression-free survival after AHSCT are shown by Kaplan-Meier
analysis (A) in the whole patient cohort and in subgroups stratified according to the factors
identified by multivariate analysis as affecting progression-free survival, respectively: (B) in
quartiles according to age (p = 0.022 for trend); (C) in patients with relapsing-remitting
(RR), secondary progressive (SP) and primary progressive (PP) forms of MS (p = 0.007 for
heterogeneity); and (D) in patients who received 1–2 or 3 previous disease-modifying
treatments (p= 0.008 for heterogeneity). The different shades of grey represent 95%
Confidence Intervals for each K-M line.
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Figure 2. Evolution of EDSS scores before and after AHSCT in relapsing and progressive MS
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The individual (colored dotted) and integrated (solid black) lines depict the evolution of
EDSS scores in the subset of patients who had both longitudinal pre-transplantation and
post-transplant EDSS data and the date of EDSS assessment documented (n =111). These
are subdivided in relapsing (A; n = 32) and progressive (B; n = 79) forms of MS at the time
of transplant. Rapid worsening of disability was observed prior to transplant in both
subgroups, as expected for patients with aggressive forms of MS who were selected for
AHSCT. The integrated line suggests that on average the accrual of disability was stopped in
relapsing MS patients during the first 2 years post-transplant.
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Figure 3. Overall survival
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The probability of survival after AHSCT is shown as Kaplan-Meier analysis in the whole
patient cohort (A). Since higher baseline EDSS score was found by multivariate analysis to
be independently associated with worse survival (see Table 2 for details) we show in (B) the
probabilities of survival after AHSCT in three strata of patients with different levels of
disability at baseline assessment (Expanded Disability Status Scale, EDSS brackets: 0–5.5;
6–6.5; ≥7), which differed significantly for the highest EDSS bracket (p = 0.004 for
heterogeneity). The grey shades represent 95% Confidence Intervals for each K-M line.
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Demographic and clinical characteristics of patients

Number of patients
Number of centers

CIBMTR

EBMT

TOTAL

111

170

281

8

17

25

40 (26 – 60)

35 (15–65)

37 (15–65)

10–19

0 (0%)

6 (4%)

6 (2%)

20–29

11 (10%)

47 (28%)

58 (21%)

30–39

40 (36%)

67 (39%)

107 (38%)

40–49

44 (40%)

41 (24%)

85 (30%)

50+

16 (14%)

9 (5%)

25 (9%)

Male

48 (43%)

69 (41%)

117 (42%)

Female

63 (57%)

101 (59%)

164 (58%)

111 (100%)

170 (100%)

281(100%)

6.5 (2.5–9)

6.5 (1.5–9)

6.5 (1.5–9)

62 (56%)

39 (20%)

101 (36%)

Age, median (range), years

Gender
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EDSS prior to mobilization
N evaluated
median (range)
EDSS prior to conditioning
Missing
N evaluated
median (range)

49 (44%)

131 (80%)

180 (64%)

6.0 (3.5–9.0)

6.5 (1.5–9.5)

6.0 (1.5–9.5)

Number of MS treatments1 prior to transplant
Missing
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5

27

32

N evaluated

106

143

249

1 treatment

42 (40%)

36 (25%)

78 (28%)

2 treatments

30 (28%)

33 (26%)

63 (22%)

>2 treatments

34 (32%)

74 (52%)

108 (38%)

12 (11%)

34 (20%)2

46 (16%)

--

17 (10%)

17 (6%)

Disease status at baseline
Relapsing remitting
Progressive relapsing
Primary progressive

16 (14%)

16 (9%)

32 (11%)

Secondary progressive

83 (75%)

103 (61%)

186 (66%)

110 (99%)

170 (100%)

280 (99%)

91 (<1–413)

77 (2–340)

81(<1–413)

N evaluated

79 (72%)

169 (99%)

248 (88%)

median (range), months

1 (<1–7)

2 (<1–9)

2 (<1–9)

24 (22%)

71 (42%)

95 (34%)

87 (78%)

99 (58%)

186 (66%)

101 (91%)

162 (95%)

263 (93%)

Time from diagnosis to transplant
N evaluated
median (range), months
Time from mobilization to transplant
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Year of transplant
1995–2000
2001–2006
Chemo- mobilization3

JAMA Neurol. Author manuscript; available in PMC 2017 December 27.

Muraro et al.

Page 19

CIBMTR

EBMT

TOTAL
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Graft manipulation4
Yes

53 (48)

70 (41%)

123(44%)

No

58 (52)

100 (59%)

158(56%)

43 (39%)

10 (6%)

53 (19%)

CY+TBI+ATG

28 (25%)

0

28 (10%)

BU+CY+ATG

15 (14%)

0

15 (6%)

Conditioning regimen
High Intensity

BU+ATG
Intermediate Intensity
BEAM+ATG
BEAM
CY+THIO
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TLI+Melphalan
BCNU+CY+ATG

0

10 (6%)

10 (3%)

28 (25%)

151 (89%)

179 (64%)

23 (21%)

86 (51%)

109 (39%)

0

40 (24%)

40 (14%)

0

7 (4%)

7 (3%)

5 (4%)

0

5 (2%)

0

18 (10%)

18 (6%)

Low Intensity

40 (36%)

9 (5%)

49 (17%)

CY+ATG

37 (33%)

9 (5%)

46 (16%)

3 (3%)

0

3 (1%)

104 (94%)

128 (75%)

232 (83%)

CY+FLUD
ATG

1

Indicates the number of disease modifying therapies received for treatment of MS prior to AHSCT

2

Includes one case reported as Marburg-type MS

3

Indicates whether a chemotherapy was associated to Growth Factors to mobilize Hematopoietic Stem Cells

4

Indicates whether manipulation of the graft was carried out; either with CD34 selection or T cell depletion
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Abbreviations: EDSS=Expanded Disability Status Scale, range 0–10, 0=no disability, 10= dead; ATG, antithymocyte globulin; BEAM,
carmustine, etoposide, cytarabine and melphalan; BCNU, carmustine; Bu, busulfan; CY, cyclophosphamide; FLUD, fludarabine; TBI, total body
irradiation; THIO, thiotepa; TLI, total lymphoid irradiation.

Author Manuscript
JAMA Neurol. Author manuscript; available in PMC 2017 December 27.

